We are live on ! Find out more
CERE

Cerevel Therapeutics Holdings, Inc. Common Stock
CERE

Delisted

CERE was delisted on the 31st of July, 2024.

Back to rankings

195 hedge funds and large institutions have $6.64B invested in Cerevel Therapeutics Holdings, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 91 funds opening new positions, 61 increasing their positions, 33 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

507% more first-time investments, than exits

New positions opened: 91 | Existing positions closed: 15

175% more funds holding in top 10

Funds holding in top 10: 4 → 11 (+7)

116% more capital invested

Capital invested by funds: $3.07B → $6.64B (+$3.57B)

85% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 33

64% more funds holding

Funds holding: 119 → 195 (+76)

3% more call options, than puts

Call options by funds: $79.6M | Put options by funds: $77.1M

Holders
195
Holders Change
+76
Holders Change %
+63.87%
% of All Funds
2.84%
Holding in Top 10
11
Holding in Top 10 Change
+7
Holding in Top 10 Change %
+175%
% of All Funds
0.16%
New
91
Increased
61
Reduced
33
Closed
15
Calls
$79.6M
Puts
$77.1M
Net Calls
+$2.49M
Net Calls Change
+$1.82M

Top Buyers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
+$190M
2
BCI
Bain Capital Investors
Massachusetts
+$157M
3
Fidelity International
Fidelity International
Bermuda
+$79.5M
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$54.9M
5
UOC
UBS O'Connor
Illinois
+$49.6M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$400M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$137M
3
AG
Artal Group
Luxembourg
-$46.9M
4
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
-$39.8M
5
Millennium Management
Millennium Management
New York
-$29.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
HS
76
HighVista Strategies
Massachusetts
$4.12M +$2.08M +72,313 +291%
RhumbLine Advisers
77
RhumbLine Advisers
Massachusetts
$4M +$190K +6,626 +8%
Man Group
78
Man Group
United Kingdom
$3.89M +$2.64M +91,860 New
Hudson Bay Capital Management
79
Hudson Bay Capital Management
Connecticut
$3.71M +$1.07M +37,400 +75%
UBS AM
80
UBS AM
Illinois
$3.59M +$394K +13,697 +19%
LSAG
81
Lake Street Advisors Group
New Hampshire
$3.56M – – –
HF
82
HRT Financial
New York
$3.49M +$2.37M +82,326 New
Squarepoint
83
Squarepoint
New York
$3.48M +$1.65M +57,327 +231%
Verition Fund Management
84
Verition Fund Management
Connecticut
$3.39M +$2.3M +80,000 New
California State Teachers Retirement System (CalSTRS)
85
California State Teachers Retirement System (CalSTRS)
California
$3.17M +$161K +5,601 +8%
PCM
86
Prelude Capital Management
New York
$3.1M +$2.1M +73,031 New
Bank of America
87
Bank of America
North Carolina
$3.07M -$1.99M -69,220 -49%
Legal & General Group
88
Legal & General Group
United Kingdom
$2.99M +$300K +10,440 +17%
Comerica Bank
89
Comerica Bank
Texas
$2.97M +$2.01M +69,950 New
Ensign Peak Advisors
90
Ensign Peak Advisors
Utah
$2.83M +$1.07M +37,365 +128%
VOYA Investment Management
91
VOYA Investment Management
Georgia
$2.72M +$1.13M +39,319 +159%
HighTower Advisors
92
HighTower Advisors
Illinois
$2.66M -$322K -11,212 -15%
GI
93
GAMCO Investors
Connecticut
$2.64M +$1.79M +62,282 New
State of Wisconsin Investment Board
94
State of Wisconsin Investment Board
Wisconsin
$2.47M +$165K +5,727 +11%
CSS
95
Cubist Systematic Strategies
Connecticut
$2.33M +$1.58M +54,975 New
VI
96
Vestcor Inc
New Brunswick, Canada
$2.12M +$1.44M +50,000 New
OR
97
Olympiad Research
Connecticut
$2.01M +$1.36M +47,304 New
CG
98
Carmignac Gestion
France
$1.87M +$1.27M +44,181 New
BCM
99
Bayesian Capital Management
New York
$1.84M +$417K +14,500 +50%
Skandinaviska Enskilda Banken (SEB)
100
Skandinaviska Enskilda Banken (SEB)
Sweden
$1.74M +$1.18M +41,000 New
2 3
4
5 6

CERE Hedge Fund Activity: Q4 2023 in Review

195 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) for Q4 2023, worth a combined $6.64B — up 116% from $3.07B a quarter earlier.

Buyers outnumbered sellers: 91 funds opened new CERE positions and 15 closed out — a net gain of 76 holders — while 61 added to existing stakes and 33 trimmed.

The largest buyer was Avoro Capital Advisors, adding an estimated $190M. The largest seller was Fidelity Investments, cutting an estimated $400M.

  • 195 institutional investors held Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) as of Q4 2023, up from 119 in Q3 2023.
  • Funds reported $6.64B of Cerevel Therapeutics Holdings, Inc. Common Stock stock for Q4 2023, up 116% quarter-over-quarter.
  • 91 funds opened new Cerevel Therapeutics Holdings, Inc. Common Stock positions in Q4 2023 and 15 closed out, a net change of +76 holders.
  • The largest Cerevel Therapeutics Holdings, Inc. Common Stock buyer in Q4 2023 was Avoro Capital Advisors, an estimated $190M added.
  • The largest Cerevel Therapeutics Holdings, Inc. Common Stock seller in Q4 2023 was Fidelity Investments, an estimated $400M sold.

Based on aggregated 13F filings for Q4 2023.